PMC:7417114 / 57974-58439 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T283","span":{"begin":424,"end":439},"obj":"Body_part"}],"attributes":[{"id":"A283","pred":"fma_id","subj":"T283","obj":"http://purl.org/sig/ont/fma/fma82798"}],"text":"Masitinib (Masivet)\n(AB Science) Absorption: mean Tmax between 1.7 and 4.7 h; following oral administration of 8.4mg/kg (dog); good absorption/exposure with AUC (0-24 h)=4045 ng*h/mL Phase I metabolic pathways: reduction, demethylation, hydroxylation, oxidative deamination, oxidation and N-oxide formation; phase II metabolic pathways: direct conjugation of masitinib, N-demethyl metabolites and oxidative metabolites with glucuronic acid Information not available"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T13272","span":{"begin":289,"end":296},"obj":"Chemical"},{"id":"T18122","span":{"begin":291,"end":296},"obj":"Chemical"},{"id":"T40591","span":{"begin":314,"end":316},"obj":"Chemical"},{"id":"T6497","span":{"begin":359,"end":368},"obj":"Chemical"},{"id":"T63194","span":{"begin":381,"end":392},"obj":"Chemical"},{"id":"T19833","span":{"begin":407,"end":418},"obj":"Chemical"},{"id":"T42697","span":{"begin":424,"end":439},"obj":"Chemical"},{"id":"T32206","span":{"begin":435,"end":439},"obj":"Chemical"}],"attributes":[{"id":"A36956","pred":"chebi_id","subj":"T13272","obj":"http://purl.obolibrary.org/obo/CHEBI_35580"},{"id":"A66421","pred":"chebi_id","subj":"T18122","obj":"http://purl.obolibrary.org/obo/CHEBI_25741"},{"id":"A11701","pred":"chebi_id","subj":"T18122","obj":"http://purl.obolibrary.org/obo/CHEBI_29356"},{"id":"A83641","pred":"chebi_id","subj":"T40591","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A65316","pred":"chebi_id","subj":"T6497","obj":"http://purl.obolibrary.org/obo/CHEBI_63450"},{"id":"A56797","pred":"chebi_id","subj":"T63194","obj":"http://purl.obolibrary.org/obo/CHEBI_25212"},{"id":"A74550","pred":"chebi_id","subj":"T19833","obj":"http://purl.obolibrary.org/obo/CHEBI_25212"},{"id":"A98847","pred":"chebi_id","subj":"T42697","obj":"http://purl.obolibrary.org/obo/CHEBI_24298"},{"id":"A48791","pred":"chebi_id","subj":"T32206","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"}],"text":"Masitinib (Masivet)\n(AB Science) Absorption: mean Tmax between 1.7 and 4.7 h; following oral administration of 8.4mg/kg (dog); good absorption/exposure with AUC (0-24 h)=4045 ng*h/mL Phase I metabolic pathways: reduction, demethylation, hydroxylation, oxidative deamination, oxidation and N-oxide formation; phase II metabolic pathways: direct conjugation of masitinib, N-demethyl metabolites and oxidative metabolites with glucuronic acid Information not available"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1586","span":{"begin":121,"end":124},"obj":"Species"}],"attributes":[{"id":"A1586","pred":"tao:has_database_id","subj":"1586","obj":"Tax:9615"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Masitinib (Masivet)\n(AB Science) Absorption: mean Tmax between 1.7 and 4.7 h; following oral administration of 8.4mg/kg (dog); good absorption/exposure with AUC (0-24 h)=4045 ng*h/mL Phase I metabolic pathways: reduction, demethylation, hydroxylation, oxidative deamination, oxidation and N-oxide formation; phase II metabolic pathways: direct conjugation of masitinib, N-demethyl metabolites and oxidative metabolites with glucuronic acid Information not available"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T169","span":{"begin":222,"end":235},"obj":"http://purl.obolibrary.org/obo/GO_0070988"},{"id":"T170","span":{"begin":297,"end":306},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T171","span":{"begin":308,"end":326},"obj":"http://purl.obolibrary.org/obo/GO_0052697"},{"id":"T172","span":{"begin":308,"end":326},"obj":"http://purl.obolibrary.org/obo/GO_0051923"},{"id":"T173","span":{"begin":344,"end":355},"obj":"http://purl.obolibrary.org/obo/GO_0000746"}],"text":"Masitinib (Masivet)\n(AB Science) Absorption: mean Tmax between 1.7 and 4.7 h; following oral administration of 8.4mg/kg (dog); good absorption/exposure with AUC (0-24 h)=4045 ng*h/mL Phase I metabolic pathways: reduction, demethylation, hydroxylation, oxidative deamination, oxidation and N-oxide formation; phase II metabolic pathways: direct conjugation of masitinib, N-demethyl metabolites and oxidative metabolites with glucuronic acid Information not available"}

{"project":"LitCovid-sentences","denotations":[{"id":"T482","span":{"begin":0,"end":19},"obj":"Sentence"},{"id":"T483","span":{"begin":20,"end":465},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Masitinib (Masivet)\n(AB Science) Absorption: mean Tmax between 1.7 and 4.7 h; following oral administration of 8.4mg/kg (dog); good absorption/exposure with AUC (0-24 h)=4045 ng*h/mL Phase I metabolic pathways: reduction, demethylation, hydroxylation, oxidative deamination, oxidation and N-oxide formation; phase II metabolic pathways: direct conjugation of masitinib, N-demethyl metabolites and oxidative metabolites with glucuronic acid Information not available"}